Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praecis/Amgen Abarelix-Depot Spares Patients Initial Testosterone Surge

Executive Summary

Praecis/Amgen's abarelix-depot lowers testosterone levels in prostate cancer patients without the initial testosterone surge associated with luteinizing hormone releasing hormone agonists such as TAP's Lupron Depot, according to posters presented May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.

You may also be interested in...



Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"

Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).

Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"

Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).

Pharmacia Trelstar Depot Approval Gives Company Prostate Cancer Therapy

Pharmacia will add a prostate cancer therapy to its oncology products portfolio following approval of Trelstar Depot June 15.

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel